Novo Nordisk A/S (NONOF)
| Previous close | 126.46 |
| Open | 127.41 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 124.22 - 130.75 |
| 52-week range | 74.70 - 140.32 |
| Volume | |
| Avg. volume | 43,352 |
| Market cap | 568.31B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 46.35 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.86 (1.47%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | N/A |
- Yahoo Finance
Novo Nordisk sales up 26% driven by GLP-1s, misses 11% on Wegovy
Novo Nordisk CEO Lars Jørgensen tells Yahoo Finance the company is confident about a robust GLP-1 sales year despite missing Wall Street estimates.
- Yahoo Finance Video
Apple, Novo Nordisk earnings, jobless claims: What to watch
A number of companies release their quarterly earning reports on Thursday, including Apple (AAPL), Novo Nordisk (NVO), Shell (SHEL), ConocoPhillips (COP), Cigna (CI), Coinbase (COIN), Moderna (MRNA), DraftKings (DKNG), Kellanova (K), United States Steel (X), and more. On the economic front, jobless claims for the week ending on April 27 will be released. Economists expect claims to rise to 212,000 from 207,000 the prior week. For more expert insight and the latest market action, click here to watch this full episode of Market Domination Overtime. This post was written by Nicholas Jacobino
- Investor's Business Daily
Novo Nordisk Dips After Wegovy Sales Double, But Miss Analysts' Forecast
Novo Nordisk stock dipped Thursday after sales of weight-loss drug, Wegovy, nearly doubled, but missed even more bullish expectations.
